KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) EBT Margin (2016 - 2025)

Historic EBT Margin for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to 2.46%.

  • Biogen's EBT Margin fell 143300.0% to 2.46% in Q4 2025 from the same period last year, while for Dec 2025 it was 15.74%, marking a year-over-year decrease of 39600.0%. This contributed to the annual value of 15.74% for FY2025, which is 39600.0% down from last year.
  • According to the latest figures from Q4 2025, Biogen's EBT Margin is 2.46%, which was down 143300.0% from 21.99% recorded in Q3 2025.
  • Biogen's 5-year EBT Margin high stood at 54.66% for Q3 2022, and its period low was 5.58% during Q3 2023.
  • For the 5-year period, Biogen's EBT Margin averaged around 19.86%, with its median value being 18.04% (2023).
  • As far as peak fluctuations go, Biogen's EBT Margin skyrocketed by 441800bps in 2022, and later tumbled by -602400bps in 2023.
  • Over the past 5 years, Biogen's EBT Margin (Quarter) stood at 14.81% in 2021, then soared by 60bps to 23.73% in 2022, then plummeted by -49bps to 12.22% in 2023, then dropped by -3bps to 11.88% in 2024, then plummeted by -121bps to 2.46% in 2025.
  • Its last three reported values are 2.46% in Q4 2025, 21.99% for Q3 2025, and 28.12% during Q2 2025.